In accordance with the provisions of the executive order , FDA assessed the costs and benefits of regulatory alternatives and appears to have selected the approach that maximizes net benefits while still meeting agency objectives .
The FDA 's assessment of the costs and benefits of regulatory alternatives have led to the proposition of an approach that neglects to maximize net benefits .